行情

DVAX

DVAX

德纳维制药
NASDAQ

实时行情|Nasdaq Last Sale

19.83
+0.23
+1.17%
盘后: 19.88 +0.05 +0.25% 19:52 09/24 EDT
开盘
19.21
昨收
19.60
最高
20.27
最低
18.90
成交量
523.56万
成交额
--
52周最高
20.66
52周最低
3.580
市值
22.76亿
市盈率(TTM)
-357.2973
分时
5日
1月
3月
1年
5年
Cramer 分享了他对 Dynavax、Nucor 和 Amarin 的看法
On CNBC's "Mad Money Lightning Round," Jim Cramer said Dynavax Technologies Corporation (NASDAQ: DVAX) is good. He loves the immuno drug stories.
Benzinga · 1天前
为什么生物制药 Dynavax 技术会在 2022 年飙升
During Thursday's Mad Money Lightning Round segment host Jim Cramer fielded questions about stocks from various callers. In the daily bar chart of DVAX, below, we can see two base patterns that have supported the rally so far. It is hard to see what the ...
TheStreet.com · 1天前
随着病毒继续蔓延,全球 Covid-19 疫苗市场预计到 2024 年将达到 250 亿美元 - 财经新闻媒体
Palm Beach, FL - September 23, 2021 – FinancialNewsMedia.com News Commentary – The growth in the COVID-19 vaccine market is projected to continue to surge through 2024. This growth is attributable to drastic surge in coronavirus cases across the world, in ...
MENAFN · 2天前
Dynavax (DVAX) 从 Clover 的 COVID-19疫苗研究数据中获益
Zacks.com · 2天前
随着病毒继续蔓延,全球 COVID-19 疫苗市场预计到 2024 年将达到 250 亿美元
PALM BEACH,  Fla., /PRNewswire/ --  - The growth in the COVID-19 vaccine market is projected to continue to surge through 2024. This growth is attributable to drastic surge in coronavirus cases across the world, in consort with combined efforts by regiona...
PR Newswire - PRF · 2天前
热门股票:SFIX 因盈利而上涨; SOFI升级; FGEN降级; DVAX数据; WKHS召回
Earnings news and analyst comments provided key themes for midday trading on Wednesday. Stitch Fix (NASDAQ:SFIX) was one of the standout gainers on the session, posting a double-digit advance after
Seekingalpha · 3天前
为什么 Dynavax Technologies 今天的股价暴涨?
Benzinga · 3天前
32 只股票在周三的午盘交易中移动
Gainers Marin Software Incorporated (NASDAQ: MRIN) shares climbed 53.1% to $8.71 following an announcement from management that the company entered into a revenue share agreement with Google LLC to develop its enterprise tech platform and software products...
Benzinga · 3天前
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解DVAX最新的财务预测,通过DVAX每股收益,每股净资产,每股现金流等数据分析德纳维制药近期的经营情况,然后做出明智的投资选择。
分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测DVAX价格均价为21.75,最高价位23.00,最低价为20.00。
EPS
机构持股
总机构数: 230
机构持股: 1.08亿
持股比例: 93.78%
总股本: 1.15亿
类型机构数股数
增持
54
787.75万
建仓
16
382.19万
减持
45
380.61万
平仓
23
190.02万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-2.13%
制药与医学研究
-1.02%
高管信息
Non-Executive Chairman/Independent Director
Andrew Hack
President/Chief Operating Officer
David Novack
Chief Executive Officer/Director
Ryan Spencer
Chief Financial Officer/Senior Vice President
Kelly MacDonald
Senior Vice President/General Counsel
John Slebir
Senior Vice President/Director of Human Resources
Jeff Coon
Senior Vice President
Robert Janssen
Senior Vice President
Dong Yu
Independent Director
Francis Cano
Independent Director
Julie Eastland
Independent Director
Daniel Kisner
Independent Director
Brent MacGregor
Independent Director
Peter Paradiso
Independent Director
Peggy Phillips
Independent Director
Natale Ricciardi
暂无数据
DVAX 简况
Dynavax Technologies Corporation是一家临床阶段的免疫治疗公司。该公司专注于通过Toll样受体(TLR)刺激平衡身体的先天和适应性免疫应答。目前,该公司正研究其用于多种癌症适应症的候选产品,用作预防乙型肝炎疫苗和哮喘疾病的改善疗法。其产品包括HEPLISAV-B、AZD1419、DV281、DV230F和DV1001。HEPLISAV-B是一种研究性成人乙型肝炎疫苗。用于治疗哮喘的AZD1419正处于开发阶段。DV281是一种研究性TLR9激动剂,专门用于向原发性肺肿瘤和肺转移瘤。DV230F用于治疗肝肿瘤。DV1001针对治疗多种恶性肿瘤的TLR 7和8激动剂。DV230F和DV1001正处于临床前开发阶段。

微牛提供Dynavax Technologies Corporation(NASDAQ-DVAX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的DVAX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易DVAX股票基本功能。